BioPharma Dive December 3, 2024
The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to $558 million.
Coherus BioSciences has reached a deal to sell another one of its biosimilars as part of a plan to make cancer immunotherapies its focus going forward.
The company on Tuesday said it will divest its Udenyca franchise, the name for its copycat version of Amgen’s Neulasta, to India-based drugmaker Intas Pharmaceuticals. Intas has agreed to pay Coherus over $483 million upfront, a figure that’ll be adjusted for the company’s inventory when the sale closes. Coherus could also get another $75 million should the drug hit certain sales targets.
Coherus intends to use a large portion of...
Today's Sponsors
Today's Sponsor